News

In the DAPA-CKD trial that featured 4,304 adult patients, Farxiga 10mg, when compared to placebo, delivered a statistically significant and clinically meaningful impact on its primary endpoint of

AI Therapeutics is a biopharmaceutical company that develops novel therapies identified through a proprietary artificial intelligence algorithm for matching drugs to new indications (Guardian Angel). The randomized, double-blind,

The investigator-initiated trial is being conducted by Hyunseok Kang, M.D., Associate Professor of Clinical Medicine at the University of California, San Francisco. Over half a million people worldwide

Remsima, which is an infliximab biosimilar, has now been indicated for the treatment of adults having ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis. Its latest approval

Both companies have decided to advance their BNT162b2 vaccine candidate into the phase 2/3 study at a 30µg dose level in a two-dose regimen after an extensive assessment

The Positive Opinion is based on data from the Phase 3 E1912 study, designed and conducted in the United States (U.S.) by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN)

Currently, DS-1062 is being developed for the treatment of non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). The TROP2 directed DXd antibody drug conjugate (ADC) is

An earlier award from BARDA for up to $483 million was entered into to support the scale up of mRNA-1273 and clinical development, originally with a smaller anticipated

Tecartus, earlier known as KTE-X19, is claimed to be the first and only approved chimeric antigen receptor (CAR) T cell therapy to treat relapsed or refractory MCL. Tecartus,